Merz Aesthetics’ Post

Reflecting on success (the achievement of particular aims) at a panel discussion led by Robyn Lindner at #ausmedtech2024: ⭐️ Jerneen Williams celebrates how Bellberry, soon to celebrate its 20th anniversary, research ⭐️ Marjan Mikel noting that success is a journey and that sometimes you need to move beyond what your customers think they need to what they actually need. As your strategy evolves, you need new skills and new people. Respiri Limited ⭐️ Sam Lanyon on the ups and downs, including an unexpected FDA rejection (and it’s better to address rather than challenge their concerns!). Stay focused and be flexible! Lumos Diagnostics ⭐️ Paul Anderson on the importance of partnering well to go international, on working with brave patients to transform their lives, having a world class board to lead the organisation’s growth

Recapping an amazing couple of days at Advanced Therapies blown away by the groundbreaking work being showcased. Here's a quick rundown of some standout contributions I listened to: Stefanie Urlinger, Cimeio Therapeutics: 💡 Revolutionising the battle against Acute Myeloid Leukemia with a novel molecular shielding technique. 💡 Their approach, focusing on CD45 targeting and modernised HSC Transplant, shows promise for full tumour eradication. Stephen Sullivan, PhD, MBA, FRSM, iPSirius: 💡 Pioneering stem cell-based immunotherapies for Non-Small Cell Lung Cancer, aiming at relapse prevention and treatment-resistant forms. 💡 Innovative vaccine strategy to modulate the tumour microenvironment, enhancing treatment efficacy. John Maher, Leucid Bio: 💡 Advancing CAR T-cell therapies for head and neck cancers, showcasing safety and disease stabilisation. 💡 Their work highlights a meticulous manufacturing process and the potential for systemic disease management. Kilian Kelly, Cynata Therapeutics: 💡 Leading with MSCs derived from iPSCs to address critical challenges in regenerative medicine. 💡 Their strategic partnership with Fujifilm and landmark clinical trials underscore their commitment to innovation and patient care. #AdvancedTherapies2024 #MedicalBreakthroughs #InnovationInHealthcare

⏰ Enrollments for RX on Board are closing today March 18th at midnight CET! https://lnkd.in/e58GuenE 🌱 Join our 12-week RX on Board: Regenerative Business Innovation online program. Our initiative goes beyond mere adaptation - it's about becoming the stewards of innovation, reimagining and activating business success with wellbeing, through ecosystem collaborations while fostering social and environmental responsibility. With guest experts and speakers, such as Niels de Fraguier, diving in to diverse topics and regenerative principles, for all of life 💚 https://lnkd.in/dyyh87ET 🦋 Facilitated by Canay Atalay Rudy de Waele Denise Terry Hontiveros Katherine Long and Danielle Shingleton 🔗 Click here to view the program overview 🌊 https://lnkd.in/ekwy6-wX 🌐 Whether you're a C-suite executive, a founder, a leader in academia, a regenerator, an NGO or a family office, if you share a passion for innovation and creating positive change in business, society and environment, with an open mind, this is your place. #regeneration #regenerative #regenerativeleadership #regenerativedesign #regenerativebusiness #innovation #leadership #leadershipdevelopment #rxonboard #regeneratex #ai #artificialintelligence #regenerativeai #graciousai

✨️ Get an insider's view of what makes us stand out in the competitive #CDMO market! Our CEO Dr. Andreas Raabe and CCO Henny Zijlstra, share insightful perspectives on our customized and personalized offers. More about it in the video ⤵️ #WeAreAdragos #GlobalPartner

📈 Eyeonic's Quarterly Business Review: Driving Innovation, Growth, and Impact! 💡 We're excited to share the highlights from Eyeonic's recent Quarterly Business Review, where our strong, passionate team came together to reflect on our progress, strategize for the future, and reaffirm our commitment to revolutionizing glaucoma care. Key takeaways: ✅ Major advancements in our cutting-edge technology and global reach. ✅ Impressive strides in enhancing our platform. ✅ Promising results from ongoing clinical trials and validation studies. ✅ Strong financial performance and investor confidence in our vision. As we move forward, we remain dedicated to pushing the boundaries of eye health innovation and making a lasting impact on patients' lives worldwide. #FollowUs #Innovation #GlaucomaCare #VisionForTheFuture #OnlineVisualFieldTest

Tomorrow afternoon we are live with Jeannette Bankes from Alcon. This isn't one to miss as we dive into some of the hottest topics in the industry today, as well as delving into Jeannette's unique perspective and experience. We will cover: 🔊 The current and future MedTech landscape 🔊 The importance of emotional intelligence 🔊 The different hats worn as Group President & Board Member 🔊 Assembling effective & efficient Boards 🔊 Advice for current & future leaders And of course, the opportunity for questions in real time. Register your interest via the link in the comments. #medtech #insidemedtech #executiveleadership #medtechlive

After lunch in the Saddle Room of the Shelbourne Hotel, Day 2 of #InnovationDublin24 climbs on with the “Next Opportunities and Directions in CV Medical Devices” panel session moderated by David Cassak of MedTech Strategist:   ●     Chris Eso, Vice President, Global Head Corporate and Business Development & Ventures, Medtronic ●     Virginia Giddings, Vice President Exploration, Edwards Lifesciences ●     Bruce Rosengard, M.D., Vice President and Global Lead for MedTech, Johnson & Johnson MedTech Q: What are the greatest unmet needs in cardiovascular disease today? A: Heart Failure and progression to Heart Failure. The heart failure population is heterogeneous, and the first hurdle to device innovation is finding the right patients. Today there are no solutions for patients between Stage 2 and Stage 3 of heart failure Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI

Explore the clinical white paper authored by Denal Wieczorek, Director of Brain Services at AdventHealth. Discover how pragmatic solutions tackled financial hurdles, including reimbursement concerns, yielding a positive return on investment (ROI) for the hospital. Read how stakeholder objections were met, ushering in this innovative therapy for patients. Backed by clinical outcomes and institutional backing, GammaTile Therapy at AdventHealth Orlando continues to expand, improving the lives of patients with brain tumors. #GammaTile #BrainTumorTreatment #HealthcareInnovation

Learn more about how hospitals can incorporate GammaTile in to their business!